Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVISION phase 3 study of delandistrogene moxeparvovec in Duchenne muscular dystrophy
2024-512626-28-00Phase 3Suspended
- Sponsor
- Sarepta Therapeutics
- Start
- Feb 2024
- Modality
- Gene Therapies
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Delandistrogene moxeparvovec with Placebo (2 arms). Primary endpoint: Change from baseline in total Performance of Upper Limb score. Started Feb 2024; status: suspended.
02
Drugs
delandistrogene moxeparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2024-512626-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512626-28-00.